Deslanoside
A cardiac glycoside derived from digitalis used to treat heart failure and certain abnormal heart rhythms. It works by strengthening heart muscle contractions and slowing the heart rate.
الوزن الجزيئي
943,1000 g/mol
LogP
-0,30
TPSA
282,00 Ų
قاعدة ليبينسكي للخمسة
راسب
آلية العمل
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1
InChI
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
Molecular Formula
C47H74O19
HBD / HBA
9 / 19
الروابط القابلة للدوران
10
الذرات الثقيلة
66
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
A cardiac glycoside derived from digitalis used to treat heart failure and certain abnormal heart rhythms. It works by strengthening heart muscle contractions and slowing the heart rate.
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
Yes, Deslanoside is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1614. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 28620. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="deslanoside"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/deslanoside/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/deslanoside/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/deslanoside/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="deslanoside"></drugfyi-drug>